Author's response to reviews

Title: A novel naproxen derivative capable of displaying anti-cancer and anti-metastatic properties against human breast cancer cells

Authors:

Jolly Deb (bcjd@iacs.res.in)
Joydeb Majumder (ocjm@iacs.res.in)
Siddhartha Sankar Jana (bcssj@iacs.res.in)

Version: 2
Date: 18 February 2014

Author's response to reviews:

To
The Editor-in-Chief

Dear Editor,

I am writing to submit our manuscript entitled “A novel naproxen derivative capable of displaying anti-cancer and anti-metastatic properties against human breast cancer cells” for publication as an article in your esteemed journal BMC Cancer.

Here, we report a new peptide based bioconjugate derived from a non-steroidal anti-inflammatory drug (NSAID) namely naproxen (Np) capable of displaying significant anti-cancer property against two human breast cancer cell lines, MCF-7 and MDA-MB-231. We have demonstrated that the enhanced anti-cancer property is due to induction of an early caspase-mediated apoptosis rather than cell-cycle arrest. Furthermore, by employing MDA-MB-231, we have showed that our compound is capable of reducing inflammatory PGE2 synthesis and delay in vitro cancer cell metastasis; a key requirement to combat secondary breast tumor. Due to its excellent hydrogelation capability at room temperature, the possibility of using bioconjugate 4 in drug-delivery system is an added advantage.

Thus, we believe the results described in the manuscript will cater to the readership of BMC Cancer. We would like to thank you for your consideration and look forward to hearing from you soon.

Best regards,

Dr. Jolly Deb
Dept. of Biological Chemistry,
Indian Association for the Cultivation of Science
2A and 2B Raja S C Mullick Road, Jadavpur
Kolkata – 700032, West Bengal
India
Mobile: +91-9051905637
e-mail: bcjd@iacs.res.in; alternative e-mail: jolly_may2@yahoo.co.uk